Published in Health Business Week, February 2nd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Medarex.
Report 1: Medarex, Inc. (MEDX) and PharmAthene, Inc., a privately held biotechnology company focused on the development of biodefense countermeasures, announced positive phase 1 study results for Valortim (MDX-1303) in healthy volunteers.
Valortim is a fully human antibody against anthrax infection developed using Medarex's UltiMAb human antibody development system. The study results were presented in October 2006 at the Infectious Diseases Society of America (IDSA)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.